Cliff Asness AQR Capital Management
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$237M |
| 2 |
Pfizer
PFE
|
+$200M |
| 3 |
Moderna
MRNA
|
+$143M |
| 4 |
EPAM Systems
EPAM
|
+$106M |
| 5 |
Gilead Sciences
GILD
|
+$94.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$138M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$135M |
| 3 |
AngloGold Ashanti
AU
|
+$112M |
| 4 |
Costco
COST
|
+$111M |
| 5 |
Microsoft
MSFT
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.96% |
| 2 | Healthcare | 15.73% |
| 3 | Financials | 11.78% |
| 4 | Industrials | 11.76% |
| 5 | Consumer Discretionary | 10.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.51T
| $1.83B | 3.48% |
10,508,458
-506,234
| -5% | -$85.1M |
|
|
2
Microsoft
MSFT
$3.59T
| $1.68B | 3.19% |
5,443,421
-369,133
| -6% | -$111M |
|
3
Alphabet (Google) Class A
GOOGL
$4.22T
| $867M | 1.65% |
6,237,200
-273,440
| -4% | -$37.1M |
|
4
Amazon
AMZN
$2.79T
| $763M | 1.45% |
4,681,940
-572,840
| -11% | -$88.5M |
|
5
TSMC
TSM
$2.17T
| $727M | 1.38% |
6,975,587
+390,794
| +6% | +$45.7M |
|
|
6
Meta Platforms (Facebook)
META
$1.4T
| $658M | 1.25% |
2,959,652
+948,289
| +47% | +$237M |
|
|
7
Pfizer
PFE
$160B
| $554M | 1.05% |
10,703,494
+3,857,765
| +56% | +$200M |
|
8
Johnson & Johnson
JNJ
$651B
| $528M | 1% |
2,979,996
-6,054
| -0.2% | -$1.03M |
|
|
9
Alphabet (Google) Class C
GOOG
$4.18T
| $499M | 0.95% |
3,573,260
-209,720
| -6% | -$28.5M |
|
10
Procter & Gamble
PG
$336B
| $461M | 0.88% |
3,018,504
-174,420
| -5% | -$27.3M |
|
|
11
Thermo Fisher Scientific
TMO
$233B
| $420M | 0.8% |
710,728
-235,464
| -25% | -$135M |
|
12
UnitedHealth
UNH
$350B
| $404M | 0.77% |
791,533
-39,044
| -5% | -$18.8M |
|
13
Allstate
ALL
$64.2B
| $381M | 0.72% |
2,749,344
-460,937
| -14% | -$57.9M |
|
14
Regeneron Pharmaceuticals
REGN
$85.9B
| $355M | 0.67% |
508,781
+59,162
| +13% | +$37.4M |
|
15
Tesla
TSLA
$1.43T
| $354M | 0.67% |
985,758
-205,332
| -17% | -$64M |
|
16
NVIDIA
NVDA
$5.2T
| $345M | 0.66% |
12,651,450
-1,524,920
| -11% | -$38.2M |
|
17
Walmart Inc
WMT
$825B
| $342M | 0.65% |
6,893,490
-627,648
| -8% | -$29.5M |
|
18
Berkshire Hathaway Class B
BRK.B
$1.06T
| $336M | 0.64% |
951,382
-32,080
| -3% | -$10.4M |
|
19
Cisco
CSCO
$438B
| $332M | 0.63% |
5,946,277
-967,906
| -14% | -$54.8M |
|
20
Texas Instruments
TXN
$241B
| $326M | 0.62% |
1,777,194
-182,049
| -9% | -$32.1M |
|
21
PepsiCo
PEP
$196B
| $326M | 0.62% |
1,945,196
+101,551
| +6% | +$17M |
|
22
JPMorgan Chase
JPM
$935B
| $317M | 0.6% |
2,325,183
-129,404
| -5% | -$19.1M |
|
23
Merck
MRK
$376B
| $296M | 0.56% |
3,606,498
-275,465
| -7% | -$21.7M |
|
24
AbbVie
ABBV
$468B
| $291M | 0.55% |
1,797,940
-232,348
| -11% | -$33.8M |
|
25
Accenture
ACN
$113B
| $282M | 0.54% |
836,407
-144,270
| -15% | -$48.7M |
|
Similar funds
Cliff Asness's Q1 2022 Portfolio in Review
As of Q1 2022, Cliff Asness held 2,367 positions worth $52.7B, down 4.5% from $55.2B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Cliff Asness's Q1 2022 filing shows 187 new, 1,008 increased, 966 reduced and 158 closed positions. Its largest new stake was Carnival Corporation Ltd: 1,737,168 shares worth $34.8M. The largest sale was Target, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Cliff Asness's largest Q1 2022 buy was Carnival Corporation Ltd: 1,737,168 shares worth $34.8M.
- Cliff Asness added most to Meta Platforms (Facebook) in Q1 2022, an estimated $237M increase.
- Cliff Asness's biggest Q1 2022 reduction was Target, cutting an estimated $138M.
- Cliff Asness fully exited Xilinx Inc in Q1 2022, selling an estimated $25.4M.
- Cliff Asness's ten largest holdings make up 16% of its $52.7B portfolio in Q1 2022.
- Cliff Asness opened 187 new positions and closed 158 in Q1 2022.
- Cliff Asness's portfolio value fell 4.5% quarter-over-quarter to $52.7B.
Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.